Each month the Lupus Forum Steering Committee selects the latest published original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
Literature Highlights - February 2025
Keywords:
BAFF, Belimumab, B cell depletion, CAR T cells, CD20, Lupus Erythematosus, Lupus Nephritis, Monoclonal antibody, Obinutuzumab, Renal response, Rituximab, SLE, Telitacicept
Literature Highlights - December 2024
Keywords:
Efficacy, IL-6, Tolerability, Phase 2, Safety, Cenerimod, LN, proteinuria, voclosporin, GC,
Literature Highlights - November 2024
Keywords:
systemic lupus erythematosus, randomized clinical trial, belimumab, disease activity, patient-reported outcomes, disease trajectories, Efficacy, Iberdomide, Phase 2, Safety, CLE,, SLE, Type 2 diabetes, Cardiovascular, Renal, SGLT2i
Literature Highlights - October 2024
Keywords:
arthritis, SLE, biomarkers, Real-life observational, renal response rates, safety, pharmacokinetics
Literature Highlights - September 2024
Keywords:
DS-7011a, Safety, Pharmacokinetics, Belimumab, Rituximab
Literature Highlights - August 2024
Keywords:
Biomarkers; End stage kidney disease; Remission; flares, tapering; lupus nephritis; SLE;
Literature Highlights - July 2024
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
